U.S. President Orders Expedited Access to Psychedelic Drug Treatments

The U.S. President has signed an executive order aimed at accelerating medical research and treatment access for psychedelic drugs. The directive instructs the FDA to expedite the review process for substances like ibogaine, which veteran groups suggest could be beneficial for treating post-traumatic stress disorder. This policy shift could facilitate the reclassification of these drugs for mental health conditions following successful clinical trials.